Weight Loss Drug Zepbound May Reduce Sleep Apnea, Eli Lilly Says
Lilly(US:LLY) Forbes·2024-04-17 14:48ToplineA late-stage trial of Eli Lilly’s weight loss drug Zepbound showed promising results in treating sleep apnea symptoms in obese adults, the company announced Wednesday, the latest findings suggesting popular weight loss drugs have the potential to treat conditions other than obesity or type 2 diabetes.Participants across two studies lost about 20% of their body weight while using the drug. NurPhoto via Getty Images Key FactsParticipants across two studies who used Zepbound experienced fewer AHI events ...